Mayr-Melnhof Karton (MMK) H1 2026 (Q&A) earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 (Q&A) earnings summary
25 Aug, 2026Executive summary
Adjusted EBITDA for H1 2026 nearly matched prior-year levels (like-for-like, excluding TANN), with sequential improvement over H2 2025, supported by strong Pharma & Healthcare Packaging growth, stable Food & Premium Packaging, and improved but still lower Board & Paper performance.
The Fit-For-Future (FFF) programme contributed EUR 105 million in H1 2026, exceeding expectations and mitigating lower prices, with a total P&L benefit target raised to over EUR 330 million by 2027.
Major capex projects in cost and energy efficiency are progressing as planned, including the acquisition of the Arnsberg mill, which is expected to generate synergies.
Financial highlights
Group sales for H1 2026 were EUR 1,849.3 million, down 8.9% year-over-year (incl. TANN), mainly due to lower prices and the TANN Group divestment, but stable sequentially.
Adjusted EBITDA was EUR 200.2 million, down 13.1% year-over-year (incl. TANN), but up 6.5% sequentially, with a margin of 10.8%.
Adjusted operating profit was EUR 89.8 million, down 23.1% year-over-year, but up 13.9% sequentially.
Free cash flow improved to EUR 37 million from negative EUR 205.4 million in H1 2025.
Operating cash flow was EUR 145 million, significantly better than the prior year.
Outlook and guidance
Maintenance shutdowns in H2 will have a EUR 35 million negative impact, mainly in Q3.
Higher costs for transport, energy, chemicals, wood, and recycled paper are expected due to geopolitical tensions, with subdued consumer demand persisting.
FFF programme is expected to contribute over EUR 100 million in H2 2026.
Capex benefits from Kwidzyn and other projects will mainly flow through in 2027, with annual Capex expected to normalize to EUR 180–200 million.
Slight price improvements in selected Board & Paper grades and continued growth in pharma and consumer packaging anticipated.
Latest events from Mayr-Melnhof Karton
- Stable adjusted EBITDA and strong Pharma & Healthcare Packaging growth offset market headwinds.MMK
H1 2026 - Efficiency gains and transformation drive profit growth and resilience amid market challenges.MMK
Austrian Select Conference - Adjusted operating profit up 2.8%, sales down 4.8%, dividend up 11%, and cost savings delivered.MMK
H2 2025 - Adjusted operating profit up 15% like-for-like, with €250M+ in savings targeted by 2027.MMK
H2 2025 (Q&A) - Profit surged on TANN divestment and cost programs, but sales fell and free cash flow was negative.MMK
Q3 2025 - Profits fell as lower prices and higher costs offset volume gains; recovery expected in 2025.MMK
Q3 2024 - Profitability and cash flow improved, but margins declined amid weak demand and lower prices.MMK
H1 2024 - Earnings rose sharply but free cash flow turned negative amid soft demand and overcapacity.MMK
Q1 2025 - EPS up, net debt down, but sales and margins fell amid weak demand and overcapacity.MMK
H2 2024